drugset / Trial / NCT04691661
Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a safety, tolerability, pharmacokinetic and efficacy study in subjects with Parkinson's disease
Timeline
- Start
- 2021-09-09
- Primary completion
- 2025-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Radotinib | Small molecule | 50 mg | Oral |
| Subject | Radotinib | Small molecule | 100 mg | Oral |
| Subject | Radotinib | Small molecule | 150 mg | Oral |
| Subject | Radotinib | Small molecule | 200 mg | Oral |